Key result
Primary prostatic intravascular large B-cell lymphoma requires differentiation from adenocarcinoma to ensure appropriate treatment.
Why the study?
Intravascular large B cell lymphoma is a very rare neoplasm of the prostate, and it is important to identify and differentiate it from prostatic adenocarcinoma because treatment differs.
Highlights the diagnostic dilemma and importance of differentiating primary intravascular large B cell lymphoma of the prostate from prostatic adenocarcinoma.
Clinicians should consider prostatic intravascular lymphoma in atypical cases; case reports leave open its true incidence and optimal therapy.
Intravascular large B cell lymphoma is a very rare neoplasm of prostate. It is important to identify this entity and differentiate this from prostatic adenocarcinoma as treatment is different. Here we present a rare case of primary intravascular large B cell lymphoma of the prostate.
No takes yet. Share an insight, caveat, or question.
Agarwal et al. (2022) studied this question. Primary intravascular large B cell lymphoma of the prostate is a rare neoplasm that must be differentiated from prostatic adenocarcinoma to ensure appropriate treatment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: